Tela Bio Inc
$ 0.91
-3.19%
11 Jun - close price
- Market Cap 42,174,200 USD
- Current Price $ 0.91
- High / Low $ 0.94 / 0.86
- Stock P/E N/A
- Book Value 0.14
- EPS -0.79
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -6.17 %
- 52 Week High 2.20
- 52 Week Low 0.50
About
TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$2.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-25 | 2025-11-13 | 2025-08-11 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.2144 | -0.17 | -0.19 | -0.22 | -0.25 | -0.23 | -0.42 | -0.51 | -0.23 | -0.53 | -0.45 | -0.46 |
| Estimated EPS | -0.1533 | -0.175 | -0.16 | -0.18 | -0.2075 | -0.222 | -0.4 | -0.47 | -0.5 | -0.43 | -0.49 | -0.53 |
| Surprise | -0.0611 | 0.005 | -0.03 | -0.04 | -0.0425 | -0.008 | -0.02 | -0.04 | 0.27 | -0.1 | 0.04 | 0.07 |
| Surprise Percentage | -39.8565% | 2.8571% | -18.75% | -22.2222% | -20.4819% | -3.6036% | -5% | -8.5106% | 54% | -23.2558% | 8.1633% | 13.2075% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TELA
2026-06-11 22:39:37
Joseph H. Capper has joined the board of TELA Bio, Inc. (TELA) and filed an initial statement of beneficial ownership (Form 3) as an insider. This filing simply reflects his new status as a reporting person and does not indicate any purchases, sales, or other equity transactions. The Form 3 shows that he does not beneficially own any securities in TELA Bio.
2026-06-11 22:13:01
TELA Bio director Guido Neels was granted stock awards totaling 23,600 and 11,925 shares, respectively, at a $0.00 strike price, along with two stock option grants for 17,335 and 17,550 shares at an exercise price of $0.935, expiring on June 9, 2036. These awards are routine compensation equity grants for board service, indicating no open-market buying or selling. The grants include multi-year vesting schedules tied to continued service and specific events, increasing his long-term equity exposure to TELA Bio.
2026-06-11 22:13:00
TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards, including restricted stock units and stock options, on June 9, 2026. These awards involve various vesting schedules and an exercise price of $0.935 per share for the options. Following these transactions, Nohra directly holds 23,600 shares of common stock from one grant and 11,925 shares from another.
2026-06-11 22:11:01
TELA Bio director Joseph H. Capper has received new equity awards, including restricted stock units (RSUs) and stock options, as compensation. The grants consist of 11,675 and 11,925 RSUs, and options for 17,335 and 17,550 shares with an exercise price of $0.935 per share, expiring in 2036. These awards are subject to vesting conditions tied to continued service or specific corporate events.
2026-06-11 22:10:01
TELA Bio director William J. Plovanic was granted 11,675 shares of common stock and a stock option for 17,335 shares with an exercise price of $0.935 per share. These equity awards, which vest on the earlier of June 9, 2027, the next annual stockholders' meeting, or a Change in Control, are part of his compensation. Following this grant, Plovanic directly owns 23,600 common shares and holds the option for 17,335 underlying shares.
2026-06-11 22:06:00
TELA Bio director Paul Thomas has received new equity awards, including two grants of Common Stock in the form of restricted stock units (RSUs) and two grants of stock options. The RSUs and stock options have various vesting schedules, tied to continued service, specific dates, the next annual stockholder meeting, or a Change in Control event. These grants were officially reported in an SEC Form 4 filing on June 9, 2026, and are considered compensation-related rather than open-market purchases.
